Duchenne and Becker muscular dystrophies

KM Flanigan - Neurologic clinics, 2014 - neurologic.theclinics.com
The X-linked Duchenne and Becker muscular dystrophies (DMD and BMD) are allelic disorders
occurring due to mutations in the DMD gene, which consists of 79 exons encoding the …

Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies

…, Z Fan, SJ Schatzberg, MA Styner, KM Flanigan… - Mammalian …, 2012 - Springer
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder in which the loss of
dystrophin causes progressive degeneration of skeletal and cardiac muscle. Potential …

Genetics and emerging treatments for Duchenne and Becker muscular dystrophy

N Wein, L Alfano, KM Flanigan - Pediatric Clinics, 2015 - pediatric.theclinics.com
Duchenne and Becker muscular dystrophy (DMD and BMD) are related disorders that occur
because of mutations in the DMD gene, encoding the dystrophin protein. DMD is more …

Eteplirsen for the treatment of Duchenne muscular dystrophy

…, V Malik, K Shontz, CM Walker, KM Flanigan… - Annals of …, 2013 - Wiley Online Library
Objective In prior open‐label studies, eteplirsen, a phosphorodiamidate morpholino oligomer,
enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic …

Evidence‐based path to newborn screening for Duchenne muscular dystrophy

…, C Shilling, ND Leslie, KM Flanigan… - Annals of …, 2012 - Wiley Online Library
Objective: Creatine kinase (CK) levels are increased on dried blood spots in newborns
related to the birthing process. As a marker for newborn screening, CK in Duchenne muscular …

The TREAT‐NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations

…, MI Bellgard, J Kirschner, KM Flanigan… - Human …, 2015 - Wiley Online Library
Analyzing the type and frequency of patient‐specific mutations that give rise to Duchenne
muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial …

A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy

…, K Bushby, DM Escolar, KM Flanigan… - Annals of …, 2008 - Wiley Online Library
Objective Myostatin is an endogenous negative regulator of muscle growth and a novel target
for muscle diseases. We conducted a safety trial of a neutralizing antibody to myostatin, …

Distinctive patterns of microRNA expression in primary muscular disorders

…, S Mitrani-Rosenbaum, KM Flanigan… - Proceedings of the …, 2007 - National Acad Sciences
The primary muscle disorders are a diverse group of diseases caused by various defective
structural proteins, abnormal signaling molecules, enzymes and proteins involved in …

Ataluren treatment of patients with nonsense mutation dystrophinopathy

…, GP Comi, AM Connolly, JW Day, KM Flanigan… - Muscle & …, 2014 - Wiley Online Library
Introduction: Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations
are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of …

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

…, C Campbell, RE Torricelli, RS Finkel, KM Flanigan… - The Lancet, 2017 - thelancet.com
Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare
neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of …